TRDA VS AMAM Stock Comparison

Performance

TRDA
10/100

TRDA returned -10.07% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

AMAM
100/100

AMAM returned 1,483.96% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Technicals

TRDA
71/100

TRDA receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

AMAM
21/100

AMAM receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

TRDA
10/100

TRDA has missed earnings 4 times in the last 20 quarters.

AMAM
17/100

AMAM has missed earnings 3 times in the last 20 quarters.

Profit

TRDA
10/100

Out of the last 13 quarters, TRDA has had 1 profitable quarters and has increased their profits year over year on 1 of them.

AMAM
10/100

Out of the last 14 quarters, AMAM has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

TRDA
51/100

TRDA has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.

AMAM
80/100

AMAM has had a higher than average amount of volatility over the last 12 months giving it a score of 80 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Entrada Therapeutics, Inc. Common Stock Summary

Nasdaq / TRDA

Healthcare

Biotechnology

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Ambrx Biopharma, Inc. Common Stock Summary

Nasdaq / AMAM

Healthcare

Biotechnology

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Power up your portfolio